**6. Conclusion and clinical relevance**

EOC remains a disease with a generally poor prognosis due to its asymptomatic early stages, ineffective screening mechanisms, and its predilection to develop chemoresistance with recurrence of disease. EVs are exciting within the field of EOC research because they provide the potential for many interventions that can save the lives of patients, ranging from diagnosing the cancer at earlier stages, identifying the optimal treatment for each individual patient, and even developing novel therapeutics that are more effective than the current regimens. With the ineffectiveness of screening tests, panels of EVs that can be detected in blood or urine provide hope for highly sensitive and specific tools that can give an accurate diagnosis of cancer in asymptomatic patients. Alternatively, by exploiting EVs to overcome chemoresistance, clinicians can redeploy existing treatments that typically become obsolete during a patient's disease course. The demand for new diagnostic tools and therapies for patients with EOC is high, and EVs can be the next frontier for seemingly miraculous advancements in cancer care.
